Bruno Medeiros

Publications

• Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
  Granfeldt Østgård, L. S., Medeiros, B. C., Sengeløv, H., Nørgaard, M., Andersen, M. K., & Nørgaard, J. M. (2015). Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
• Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
  Corces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014). Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 111(7), 2548-2553.
• Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
  Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., & Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893-901.
• Cytarabine Dose for Acute Myeloid Leukemia Medeiros, B. C., Othus, M., & Appelbaum, F. R. (2011). Cytarabine Dose for Acute Myeloid Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 364(22), 2167-2168.
  
• Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience Medeiros, B. C., Othus, M., Fang, M., Roulston, D., & Appelbaum, F. R. (2010). Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. BLOOD, 116(13), 2224-2228.
  
• Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. Behbehani, G. K., Samusik, N., Bjornson, Z. B., Fantl, W. J., Medeiros, B. C., & Nolan, G. P. (2015). Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. Cancer discovery, 5(9), 988-1003.
  
• Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis Percival, M.-E. M., Tao, L., Medeiros, B. C., & Clarke, C. A. (2015). Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis. CANCER, 121(12), 2004-2012.
  
• Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Swords, R. T., Erba, H. P., DeAngelo, D. J., Bixby, D. L., Altman, J. K., & Medeiros, B. C. (2015). Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. British journal of haematology, 169(4), 534-543.
  
• G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. Becker, P. S., Medeiros, B. C., Stein, A. S., Othus, M., Appelbaum, F. R., & Estey, E. H. (2015). G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. American journal of hematology, 90(4), 295-300.
  
• Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia Medeiros, B. C., Othus, M., Fang, M., Appelbaum, F. R., & Erba, H. P. (2015). Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. HAEMATOLOGICA, 100(3), 331-335.
  
• Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., & Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature medicine, 21(2), 178-184.
  
• Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., & Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. NATURE MEDICINE, 21(2), 90-96.
  
• Increased plasma D-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm Rakheja, D., Fuda, F., Vandergriff, T., Boriack, R., Medeiros, B. C., & Chen, W. (2015). Increased plasma D-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm. HUMAN PATHOLOGY, 46(2), 322-326.
  
• Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Medeiros, B. C., Satram-Hoang, S., Hurst, D., Hoang, K. Q., Momin, F., & Reyes, C. (2015). Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Annals of hematology.
  
• Chemotherapy options for previously untreated acute myeloid leukemia Lynch, R. C., & Medeiros, B. C. (2015). Chemotherapy options for previously untreated acute myeloid leukemia. EXPERT OPINION ON PHARMACOTHERAPY, 16(14), 2149-2162.
  
• Sequential Azacitidine plus Lenalidomide in Previously Treated Elderly Patients with Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome. Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., & Medeiros, B. C. (2015). Sequential Azacitidine plus Lenalidomide in Previously Treated Elderly Patients with Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome. Leukemia & lymphoma, 1-17.
  
• Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Pasquini, M. C., Zhang, M. J., Medeiros, B. C., Armand, P., Hu, Z. H., & Weisdorf, D. J. (2015). Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
  
• Chemotherapy dose in obese AML patients: To cap or not to cap? Percival, M.-E. M., & Medeiros, B. C. (2015). Chemotherapy dose in obese AML patients: To cap or not to cap?. LEUKEMIA RESEARCH, 39(1), 30-32.
  
• Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California. Abrahão, R., Ribeiro, R. C., Medeiros, B. C., Keogh, R. H., & Keegan, T. H. (2015). Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California. Cancer.
  
• Monosomal karyotype acute myeloid leukemia: tread lightly. Garcia, J. S., & Medeiros, B. C. (2015). Monosomal karyotype acute myeloid leukemia: tread lightly. Acta haematologica, 133(4), 324-326.
  
• Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Percival, M. E., Medeiros, B. C., Tian, L., Robeson, S., Laport, G. G., & Lowsky, R. (2015). Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone marrow transplantation.
  
• Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Khalife, J., Radomska, H. S., Santhanam, R., Huang, X., Neviani, P., & Marcucci, G. (2015). Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia.
  
• Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed phenotype acute leukemia. Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., & Gotlib, J. (2015). Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed phenotype acute leukemia. Leukemia.
  
• Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., & Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441-1445.
  
• Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Liedtke, M., Dunn, T., Dinner, S., Coutré, S. E., Berube, C., & Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leukemia research, 38(12), 1441-1445.
  
• Polypharmacy in AML: the tip of the iceberg. Patel, S., & Medeiros, B. C. (2014). Polypharmacy in AML: the tip of the iceberg. Leukemia research, 38(11), 1378-1379.
  
• Management considerations in older patients with AML: a 2014 perspective. Medeiros, B. C. (2014). Management considerations in older patients with AML: a 2014 perspective. [Rinsho ketsueki] The Japanese journal of clinical hematology, 55(10), 1803-1807.
  
• Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients Frankel, A. E., Woo, J. H., Ahn, C., Pemmaraju, N., Medeiros, B. C., & Rowinsky, E. (2014). Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. BLOOD, 124(3), 385-392.
  
• Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. Pierceall, W. E., Lena, R. J., Medeiros, B. C., Blake, N., Doykan, C., & Walter, R. B. (2014). Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia research, 38(5), 564-568.
  
• European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., & Lowsky, R. (2014). European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. BLOOD CANCER JOURNAL, 4.
  
• Senior Adult Oncology, Version 2.2014 Hurria, A., Wildes, T., Blair, S. L., Browner, I. S., Cohen, H. J., & Sundar, H. (2014). Senior Adult Oncology, Version 2.2014. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(1), 82-126.
  
• Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia. Medeiros, B. C. (2014). Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia. Acta haematologica, 131(4), 200-201.
  
• Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. Wildes, T. M., Stirewalt, D. L., Medeiros, B., & Hurria, A. (2014). Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. Journal of the National Comprehensive Cancer Network , 12(1), 128-136.
  
• Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study Walter, R. B., Medeiros, B. C., Gardner, K. M., Orlowski, K. F., Gallegos, L., & Estey, E. H. (2014). Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. HAEMATOLOGICA, 99(1), 54-59.
  
• Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. Medeiros, B. C., Othus, M., Estey, E. H., Fang, M., & Appelbaum, F. R. (2014). Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. British journal of haematology, 164(2), 245-250.
  
• Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes. Jagsi, R., Chiang, A., Polite, B. N., Medeiros, B. C., McNiff, K., & Loehrer, P. J. (2013). Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes. Journal of oncology practice / American Society of Clinical Oncology, 9(6), e290-7.
  
• A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia Patel, S., Liedtke, M., Ngo, D., & Medeiros, B. C. (2013). A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 54(10), 2231-2235.
  
• Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., & Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. HAEMATOLOGICA, 98(4), 591-596.
  
• CD11b expression and MK+ AML: A sign of impending doom? Medeiros, B. C. (2013). CD11b expression and MK+ AML: A sign of impending doom?. LEUKEMIA RESEARCH, 37(2), 121-121.
  
• 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels Pollyea, D. A., Kohrt, H. E., Zhang, B., Zehnder, J., Schenkein, D., & Medeiros, B. C. (2013). 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. LEUKEMIA & LYMPHOMA, 54(2), 408-410.
  
• CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells Kim, D., Park, C. Y., Medeiros, B. C., & Weissman, I. L. (2012). CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells. LEUKEMIA, 26(12), 2530-2537.
  
• Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).
  
• Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm Becker, P. S., Medeiros, B. C., Stein, A. S., Appelbaum, F. R., Scott, B. L., & Estey, E. H. (2012). Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. BLOOD, 120(21).
  
• A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., & Liedtke, M. (2012). A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma. BLOOD, 120(21).
  
• Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options. HEMATOLOGY, 17(6), 325-328.
  
• Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., & Shead, D. A. (2012). Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(10), 1211-1219.
  
• Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., & Shead, D. A. (2012). Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. Journal of the National Comprehensive Cancer Network , 10(10), 1211-1219.
  
• Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., & Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957-960.
  
• Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia Medeiros, B. C., Othus, M., Estey, E. H., Fang, M., & Appelbaum, F. R. (2012). Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(9), 1401-1404.
  
• Novel agents in acute myeloid leukemia Ungewickell, A., & Medeiros, B. C. (2012). Novel agents in acute myeloid leukemia. INTERNATIONAL JOURNAL OF HEMATOLOGY, 96(2), 178-185.
  
• New treatment approaches for older adults with multiple myeloma Wildes, T. M., Vij, R., Petersdorf, S. H., Medeiros, B. C., & Hurria, A. (2012). New treatment approaches for older adults with multiple myeloma. JOURNAL OF GERIATRIC ONCOLOGY, 3(3), 279-290.
  
• Blood consult: monosomal karyotype acute myeloid leukemia Garcia, J. S., Medeiros, B. C., & Appelbaum, F. R. (2012). Blood consult: monosomal karyotype acute myeloid leukemia. BLOOD, 119(24), 5659-5660.
  
• Impact of residual normal metaphases in core binding factor acute myeloid leukemia Medeiros, B. C., Othus, M., Fang, M., Appelbaum, F. R., & Estey, E. H. (2012). Impact of residual normal metaphases in core binding factor acute myeloid leukemia. CANCER, 118(9), 2420-2423.
  
• Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia Walter, R. B., Medeiros, B. C., Powell, B. L., Schiffer, C. A., Appelbaum, F. R., & Estey, E. H. (2012). Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(5), 739-742.
  
• Aggressive EBV-associated Lymphoproliferative Disorder: A Prodrome to Diffuse Large B-cell Lymphoma? Batra, R., Medeiros, B. C., Zehnder, J. L., Warnke, R. A., & Natkunam, Y. (2012). Aggressive EBV-associated Lymphoproliferative Disorder: A Prodrome to Diffuse Large B-cell Lymphoma?. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(3), 325-330.
  
• Unveiling the complexity of CK+ AML. Medeiros, B. C. (2012). Unveiling the complexity of CK+ AML. Blood, 119(9), 1958-1959.
  
• "It doesn't matter if you're black or white", does it? Medeiros, B. C. (2012). "It doesn't matter if you're black or white", does it?. LEUKEMIA RESEARCH, 36(2), 127-127.
  
• Senior Adult Oncology Hurria, A., Browner, I. S., Cohen, H. J., Denlinger, C. S., deShazo, M., & Wildes, T. (2012). Senior Adult Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(2), 162-209.
  
• Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., & Zehnder, J. L. (2012). Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(1), 45-50.
  
• Treatment advances have not improved the early death rate in acute promyelocytic leukemia McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133-136.
  
• Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., & Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30-37.
  
• Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm Becker, P. S., Medeiros, B. C., Appelbaum, F. R., Scott, B. L., Hendrie, P. C., & Estey, E. H. (2011). Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. BLOOD, 118(21), 1545-1545.
  
• Multiple Myeloma Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., & Yunus, F. (2011). Multiple Myeloma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(10), 1146-1183.
  
• Unfavorable-risk cytogenetics in acute myeloid leukemia Hong, W.-J., & Medeiros, B. C. (2011). Unfavorable-risk cytogenetics in acute myeloid leukemia. EXPERT REVIEW OF HEMATOLOGY, 4(2), 173-184.
  
• Acute myeloid leukaemia in the elderly: a review Pollyea, D. A., Kohrt, H. E., & Medeiros, B. C. (2011). Acute myeloid leukaemia in the elderly: a review. BRITISH JOURNAL OF HAEMATOLOGY, 152(5), 524-542.
  
• Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer Wang, M., Medeiros, B. C., Erba, H. P., DeAngelo, D. J., Giles, F. J., & Swords, R. T. (2011). Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. EXPERT OPINION ON THERAPEUTIC TARGETS, 15(3), 253-264.
  
• Microfluidic purification and analysis of hematopoietic stem cells from bone marrow Schirhagl, R., Fuereder, I., Hall, E. W., Medeiros, B. C., & Zare, R. N. (2011). Microfluidic purification and analysis of hematopoietic stem cells from bone marrow. LAB ON A CHIP, 11(18), 3130-3135.
  
• A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML) Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., & Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347-1347.
  
• Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., & Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357-1358.
  
• Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., & Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877-881.
  
• Plasma cell leukemia: concepts and management. Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. Expert review of hematology, 3(5), 543-549.
  
• Plasma cell leukemia: concepts and management Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. EXPERT REVIEW OF HEMATOLOGY, 3(5), 539-549.
  
• Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge Arredondo, A. R., Gotlib, J., Shier, L., Medeiros, B., Wong, K., & George, T. I. (2010). Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. AMERICAN JOURNAL OF HEMATOLOGY, 85(8), 600-606.
  
• PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML) Walter, B., Medeiros, B., Nielsen-Stoeck, M., Harrington, E., Powell, B., & Estey, E. (2010). PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML). HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 29-30.
  
• Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Medeiros, B. C., Kohrt, H. E., Arber, D. A., Bangs, C. D., Cherry, A. M., & Alizadeh, A. A. (2010). Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). LEUKEMIA RESEARCH, 34(5), 594-597.
  
• Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420-421.
  
• Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., & Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646-647.
  
• Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy Pretz, J., & Medeiros, B. C. (2009). Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy. AMERICAN JOURNAL OF HEMATOLOGY, 84(10), 698-699.
  
• NCCN clinical practice guidelines in oncology: multiple myeloma. Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., & Yunus, F. (2009). NCCN clinical practice guidelines in oncology: multiple myeloma. Journal of the National Comprehensive Cancer Network , 7(9), 908-942.
  
• Multiple Myeloma Anderson, K. C., Alsina, M., Bensinger, W., Biermann, S., Chanan-Khan, A., & Yunus, F. (2009). Multiple Myeloma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 7(9), 908-942.
  
• Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., & Zehnder, J. (2009). Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia Medeiros, B. C. (2009). Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 360(17), 1787-1787.
  
• Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia Medeiros, B. C. (2009). Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(12), 2105-2105.
  
• Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia Medeiros, B. C. (2009). Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(3), 474-474.
  
• Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. Chan, S. M., George, T., Cherry, A. M., & Medeiros, B. C. (2009). Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. Cases journal, 2(1), 121-?.
  
• Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study McGuire, A., Shier, L. R., Gotlib, J., Medeiros, B., Wong, K., & George, T. I. (2009). Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study. LABORATORY INVESTIGATION, 89, 277A-277A.
  
• Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581-585.
  
• Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose Interleukin-2 for treatment of metastatic renal cell carcinoma Medeiros, B. C., Kogel, K. E., & Kane, M. A. (2003). Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose Interleukin-2 for treatment of metastatic renal cell carcinoma. TRANSFUSION AND APHERESIS SCIENCE, 29(1), 25-27.